{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T07:08:11Z","timestamp":1794467291923,"version":"4.9.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"DOI":"10.1038\/s43018-025-00907-4","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T10:03:44Z","timestamp":1739181824000},"page":"474-492","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Targeting ADAR1 with a small molecule for the treatment of prostate cancer"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7848-9585","authenticated-orcid":false,"given":"Xiao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasheng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongtao","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayu","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjian","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4664-6029","authenticated-orcid":false,"given":"Shun-Qing","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0568-0645","authenticated-orcid":false,"given":"Lei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongrui","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghui","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengliang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8544-9485","authenticated-orcid":false,"given":"Yuzhang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2522-7546","authenticated-orcid":false,"given":"Haiping","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4716-5526","authenticated-orcid":false,"given":"Yibei","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2613-941X","authenticated-orcid":false,"given":"Peng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,10]]},"reference":[{"key":"907_CR1","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/s41571-020-0378-y","volume":"17","author":"F Islami","year":"2020","unstructured":"Islami, F., Siegel, R. L. & Jemal, A. The changing landscape of cancer in the USA\u2014opportunities for advancing prevention and treatment. Nat. Rev. Clin. Oncol. 17, 631\u2013649 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"907_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA Cancer J. Clin. 74, 12\u201349 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"907_CR3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"907_CR4","doi-asserted-by":"publisher","first-page":"103199","DOI":"10.1016\/j.critrevonc.2020.103199","volume":"157","author":"N Brighi","year":"2021","unstructured":"Brighi, N. et al. The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectives. Crit. Rev. Oncol. Hematol. 157, 103199 (2021).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"907_CR5","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1038\/s43018-020-00125-0","volume":"1","author":"JM Arriaga","year":"2020","unstructured":"Arriaga, J. M. et al. A MYC and RAS co-activation signature in localized prostate cancer drives bone metastasis and castration resistance. Nat. Cancer 1, 1082\u20131096 (2020).","journal-title":"Nat. Cancer"},{"key":"907_CR6","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1158\/2159-8290.CD-20-0751","volume":"11","author":"J Welti","year":"2021","unstructured":"Welti, J. et al. Targeting the p300\/CBP axis in lethal prostate cancer. Cancer Discov. 11, 1118\u20131137 (2021).","journal-title":"Cancer Discov."},{"key":"907_CR7","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.celrep.2015.08.080","volume":"13","author":"N Paz-Yaacov","year":"2015","unstructured":"Paz-Yaacov, N. et al. Elevated RNA editing activity is a major contributor to transcriptomic diversity in tumors. Cell Rep. 13, 267\u2013276 (2015).","journal-title":"Cell Rep."},{"key":"907_CR8","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41586-018-0768-9","volume":"565","author":"JJ Ishizuka","year":"2019","unstructured":"Ishizuka, J. J. et al. Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade. Nature 565, 43\u201348 (2019).","journal-title":"Nature"},{"key":"907_CR9","doi-asserted-by":"publisher","first-page":"321","DOI":"10.4161\/rna.23343","volume":"10","author":"T Shimokawa","year":"2013","unstructured":"Shimokawa, T. et al. RNA editing of the GLI1 transcription factor modulates the output of Hedgehog signaling. RNA Biol. 10, 321\u2013333 (2013).","journal-title":"RNA Biol."},{"key":"907_CR10","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1182\/blood-2018-02-832576","volume":"132","author":"PJ Teoh","year":"2018","unstructured":"Teoh, P. J. et al. Aberrant hyperediting of the myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosis. Blood 132, 1304\u20131317 (2018).","journal-title":"Blood"},{"key":"907_CR11","doi-asserted-by":"publisher","first-page":"eaah3941","DOI":"10.1126\/scisignal.aah3941","volume":"10","author":"EM Amin","year":"2017","unstructured":"Amin, E. M. et al. The RNA-editing enzyme ADAR promotes lung adenocarcinoma migration and invasion by stabilizing FAK. Sci. Signal. 10, eaah3941 (2017).","journal-title":"Sci. Signal."},{"key":"907_CR12","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1158\/0008-5472.CAN-13-2545","volume":"74","author":"Y-R Qin","year":"2014","unstructured":"Qin, Y.-R. et al. Adenosine-to-inosine RNA editing mediated by ADARs in esophageal squamous cell carcinoma. Cancer Res. 74, 840\u2013851 (2014).","journal-title":"Cancer Res."},{"key":"907_CR13","first-page":"148","volume":"10","author":"Y Sun","year":"2020","unstructured":"Sun, Y. et al. The aberrant expression of ADAR1 promotes resistance to BET inhibitors in pancreatic cancer by stabilizing c-Myc. Am. J. Cancer Res. 10, 148\u2013163 (2020).","journal-title":"Am. J. Cancer Res."},{"key":"907_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07824-4","volume":"9","author":"HS Gannon","year":"2018","unstructured":"Gannon, H. S. et al. Identification of ADAR1 adenosine deaminase dependency in a subset of cancer cells. Nat. Commun. 9, 5450 (2018).","journal-title":"Nat. Commun."},{"key":"907_CR15","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature24041","volume":"550","author":"MH Tan","year":"2017","unstructured":"Tan, M. H. et al. Dynamic landscape and regulation of RNA editing in mammals. Nature 550, 249\u2013254 (2017).","journal-title":"Nature"},{"key":"907_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43633-0","volume":"14","author":"MS Zambrano-Mila","year":"2023","unstructured":"Zambrano-Mila, M. S. et al. Dissecting the basis for differential substrate specificity of ADAR1 and ADAR2. Nat. Commun. 14, 8212 (2023).","journal-title":"Nat. Commun."},{"key":"907_CR17","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3389\/fonc.2019.00349","volume":"9","author":"G Dhiman","year":"2019","unstructured":"Dhiman, G. et al. Metadherin: a therapeutic target in multiple cancers. Front. Oncol. 9, 349 (2019).","journal-title":"Front. Oncol."},{"key":"907_CR18","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1158\/0008-5472.CAN-20-1876","volume":"81","author":"M Shen","year":"2021","unstructured":"Shen, M. et al. Therapeutic targeting of metadherin suppresses colorectal and lung cancer progression and metastasis. Cancer Res. 81, 1014\u20131025 (2021).","journal-title":"Cancer Res."},{"key":"907_CR19","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s43018-021-00279-5","volume":"3","author":"M Shen","year":"2022","unstructured":"Shen, M. et al. Small-molecule inhibitors that disrupt the MTDH\u2013SND1 complex suppress breast cancer progression and metastasis. Nat. Cancer 3, 43\u201359 (2022).","journal-title":"Nat. Cancer"},{"key":"907_CR20","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s43018-021-00280-y","volume":"3","author":"M Shen","year":"2022","unstructured":"Shen, M. et al. Pharmacological disruption of the MTDH\u2013SND1 complex enhances tumor antigen presentation and synergizes with anti-PD-1 therapy in metastatic breast cancer. Nat. Cancer 3, 60\u201374 (2022).","journal-title":"Nat. Cancer"},{"key":"907_CR21","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.cell.2017.12.038","volume":"172","author":"H Chung","year":"2018","unstructured":"Chung, H. et al. Human ADAR1 prevents endogenous RNA from triggering translational shutdown. Cell 172, 811\u2013824 (2018).","journal-title":"Cell"},{"key":"907_CR22","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41388-020-01515-5","volume":"40","author":"C-P Kung","year":"2021","unstructured":"Kung, C.-P. et al. Evaluating the therapeutic potential of ADAR1 inhibition for triple-negative breast cancer. Oncogene 40, 189\u2013202 (2021).","journal-title":"Oncogene"},{"key":"907_CR23","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.stem.2016.05.004","volume":"19","author":"MA Zipeto","year":"2016","unstructured":"Zipeto, M. A. et al. ADAR1 activation drives leukemia stem cell self-renewal by impairing let-7 biogenesis. Cell Stem Cell 19, 177\u2013191 (2016).","journal-title":"Cell Stem Cell"},{"key":"907_CR24","doi-asserted-by":"publisher","first-page":"10867","DOI":"10.1021\/ja029742d","volume":"125","author":"EA V\u00e9liz","year":"2003","unstructured":"V\u00e9liz, E. A., Easterwood, L. M. & Beal, P. A. Substrate analogues for an RNA-editing adenosine deaminase: mechanistic investigation and inhibitor design. J. Am. Chem. Soc. 125, 10867\u201310876 (2003).","journal-title":"J. Am. Chem. Soc."},{"key":"907_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18862-2","volume":"11","author":"S Park","year":"2020","unstructured":"Park, S. et al. High-throughput mutagenesis reveals unique structural features of human ADAR1. Nat. Commun. 11, 5130 (2020).","journal-title":"Nat. Commun."},{"key":"907_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-014-0370-3","volume":"13","author":"LA Crews","year":"2015","unstructured":"Crews, L. A. et al. An RNA editing fingerprint of cancer stem cell reprogramming. J. Transl. Med. 13, 52 (2015).","journal-title":"J. Transl. Med."},{"key":"907_CR27","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s12519-022-00679-2","volume":"19","author":"GB Dell\u2019Isola","year":"2023","unstructured":"Dell\u2019Isola, G. B. et al. Clinical spectrum and currently available treatment of type I interferonopathy Aicardi\u2013Gouti\u00e8res syndrome. World J. Pediatr. 19, 635\u2013643 (2023).","journal-title":"World J. Pediatr."},{"key":"907_CR28","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1038\/ng.2414","volume":"44","author":"GI Rice","year":"2012","unstructured":"Rice, G. I. et al. Mutations in ADAR1 cause Aicardi\u2013Gouti\u00e8res syndrome associated with a type I interferon signature. Nat. Genet. 44, 1243\u20131248 (2012).","journal-title":"Nat. Genet."},{"key":"907_CR29","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1055\/s-0037-1601449","volume":"48","author":"GI Rice","year":"2017","unstructured":"Rice, G. I. et al. Genetic, phenotypic, and interferon biomarker status in ADAR1-related neurological disease. Neuropediatrics 48, 166\u2013184 (2017).","journal-title":"Neuropediatrics"},{"key":"907_CR30","doi-asserted-by":"publisher","first-page":"86161","DOI":"10.18632\/oncotarget.13354","volume":"7","author":"N Dou","year":"2016","unstructured":"Dou, N. et al. Aberrant overexpression of ADAR1 promotes gastric cancer progression by activating mTOR\/p70S6K signaling. Oncotarget 7, 86161\u201386173 (2016).","journal-title":"Oncotarget"},{"key":"907_CR31","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/nm.3043","volume":"19","author":"L Chen","year":"2013","unstructured":"Chen, L. et al. Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma. Nat. Med. 19, 209\u2013216 (2013).","journal-title":"Nat. Med."},{"key":"907_CR32","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41591-021-01244-6","volume":"27","author":"MX He","year":"2021","unstructured":"He, M. X. et al. Transcriptional mediators of treatment resistance in lethal prostate cancer. Nat. Med. 27, 426\u2013433 (2021).","journal-title":"Nat. Med."},{"key":"907_CR33","doi-asserted-by":"publisher","first-page":"632187","DOI":"10.3389\/fonc.2020.632187","volume":"10","author":"H Wang","year":"2020","unstructured":"Wang, H., Chen, S., Wei, J., Song, G. & Zhao, Y. A-to-I RNA editing in cancer: from evaluating the editing level to exploring the editing effects. Front. Oncol. 10, 632187 (2020).","journal-title":"Front. Oncol."},{"key":"907_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-021-02271-9","volume":"22","author":"V Tassinari","year":"2021","unstructured":"Tassinari, V. et al. ADAR1 is a new target of METTL3 and plays a pro-oncogenic role in glioblastoma by an editing-independent mechanism. Genome Biol. 22, 51 (2021).","journal-title":"Genome Biol"},{"key":"907_CR35","doi-asserted-by":"publisher","first-page":"4904","DOI":"10.1158\/0008-5472.CAN-20-1228","volume":"80","author":"E Beketova","year":"2020","unstructured":"Beketova, E. et al. Protein arginine methyltransferase 5 promotes pICln-dependent androgen receptor transcription in castration-resistant prostate cancer. Cancer Res. 80, 4904\u20134917 (2020).","journal-title":"Cancer Res."},{"key":"907_CR36","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1101\/gr.242636.118","volume":"29","author":"K Licht","year":"2019","unstructured":"Licht, K. et al. A high resolution A-to-I editing map in the mouse identifies editing events controlled by pre-mRNA splicing. Genome Res. 29, 1453\u20131463 (2019).","journal-title":"Genome Res."},{"key":"907_CR37","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1038\/s41592-019-0610-9","volume":"16","author":"SH Roth","year":"2019","unstructured":"Roth, S. H., Levanon, E. Y. & Eisenberg, E. Genome-wide quantification of ADAR adenosine-to-inosine RNA editing activity. Nat. Methods 16, 1131\u20131138 (2019).","journal-title":"Nat. Methods"},{"key":"907_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30581-4","volume":"13","author":"K Yuan","year":"2022","unstructured":"Yuan, K. et al. Targeting dual-specificity tyrosine phosphorylation-regulated kinase 2 with a highly selective inhibitor for the treatment of prostate cancer. Nat. Commun. 13, 2903 (2022).","journal-title":"Nat. Commun."}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-00907-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-00907-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-00907-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T05:22:21Z","timestamp":1743139341000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-00907-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,10]]},"references-count":38,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["907"],"URL":"https:\/\/doi.org\/10.1038\/s43018-025-00907-4","relation":{},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,10]]},"assertion":[{"value":"16 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}